A worldwide survey on perioperative antimicrobial prophylaxis for heart transplantation: From theory to clinical practice.
MDRO
antimicrobial prophylaxis
heart transplantation
screening swabs
survey
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
revised:
18
01
2023
received:
16
11
2022
accepted:
02
02
2023
medline:
11
4
2023
pubmed:
8
3
2023
entrez:
7
3
2023
Statut:
ppublish
Résumé
The aim of our survey was to analyze the current attitudes toward antimicrobial prophylaxis in heart transplanting centers worldwide. The survey was composed of a total of 50 questions, it consisted of four different sections as follows. The first section collected physicians' personal data and centers' general characteristics, second assessed the approach to patients colonized with multidrug-resistant organisms (MDROs), while the third consisted of the infection risk related to cardiovascular devices, and antimicrobial treatment data, the last focused on donor's colonization. A total of 56 answers from 26 different countries were collected, mostly from Europe (n = 30) and the USA (n = 16). A first-generation cephalosporin (58.9%) or a combination therapy with vancomycin (10.7%) were the most frequently prescribed antimicrobial prophylaxis. Roughly 30% of the centers used different antimicrobial prophylaxis,mostly including Gram negative bacteria coverage. The frequency of screening for multidrug resistant Gram-negative bacteria was higher in Europe, where the percentage of centers providing screening for extended spectrum beta-lactamase (46.7%) and carbapenem-resistant Enterobacteriaceae (CRE) (53.3%) was higher than in other geographic area (p = .019; p = .013, respectively). This survey highlights a heterogeneity of clinical practice concerning antimicrobial prophylaxis at transplant. The concern for potential Gram-negative bacteria infection was responsible for broader antimicrobial coverage in 30% of centers.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of our survey was to analyze the current attitudes toward antimicrobial prophylaxis in heart transplanting centers worldwide.
METHODS
METHODS
The survey was composed of a total of 50 questions, it consisted of four different sections as follows. The first section collected physicians' personal data and centers' general characteristics, second assessed the approach to patients colonized with multidrug-resistant organisms (MDROs), while the third consisted of the infection risk related to cardiovascular devices, and antimicrobial treatment data, the last focused on donor's colonization.
RESULTS
RESULTS
A total of 56 answers from 26 different countries were collected, mostly from Europe (n = 30) and the USA (n = 16). A first-generation cephalosporin (58.9%) or a combination therapy with vancomycin (10.7%) were the most frequently prescribed antimicrobial prophylaxis. Roughly 30% of the centers used different antimicrobial prophylaxis,mostly including Gram negative bacteria coverage. The frequency of screening for multidrug resistant Gram-negative bacteria was higher in Europe, where the percentage of centers providing screening for extended spectrum beta-lactamase (46.7%) and carbapenem-resistant Enterobacteriaceae (CRE) (53.3%) was higher than in other geographic area (p = .019; p = .013, respectively).
CONCLUSION
CONCLUSIONS
This survey highlights a heterogeneity of clinical practice concerning antimicrobial prophylaxis at transplant. The concern for potential Gram-negative bacteria infection was responsible for broader antimicrobial coverage in 30% of centers.
Substances chimiques
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14034Informations de copyright
© 2023 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195-283. doi:10.2146/ajhp120568
Gouvêa M, Novaes Cde O, Pereira DM, Iglesias AC. Adherence to guidelines for surgical antibiotic prophylaxis: a review. Braz J Infect Dis. 2015;19(5):517-524. doi:10.1016/j.bjid.2015.06.004
Aguado JM, Silva JT, Fernández-Ruiz M, et al. Management of multidrugresistant Gram-negative bacilli infections in solidorgantransplantrecipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev. 2018;32(1):36-57. doi:10.1016/j.trre.2017.07.001
Ramos A, Asensio A, Muñez E, Torre-Cisneros J, Blanes M. Incisional surgical infection in heart transplantation. Transpl Infect Dis. 2008;10(4):298-302. doi:10.1111/j.1399-3062.2008.00316.x
Gómez-López R, Barge-Caballero E, Fernández-Ugidos P, Paniagua-Martin MJ, Barge-Caballero G. Hospital post-operative infection after heart transplantation: epidemiology, clinical management, and outcome. SurgInfect (Larchmt). 2020;21(2):179-191. doi:10.1089/sur.2019.073
Abbo LM, Grossi PA. Surgical site infections: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13589. doi:10.1111/ctr.13589
Engelman R, Shahian D, Shemin R, Guy TS, Bratzler D, Edwards F. The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. Ann Thorac Surg. 2007 Apr;83(4):1569-1576. doi:10.1016/j.athoracsur.2006.09.046
Saraswat MK, Magruder JT, Crawford TC, et al. Preoperative Staphylococcus aureus screening and targeted decolonization in cardiac surgery. Ann Thorac Surg. 2017;104(4):1349-1356. doi:10.1016/j.athoracsur.2017.03.018
Finkelstein R, Rabino G, Mashiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg. 2002;123(2):326-332. doi:10.1067/mtc.2002.119698
Peel T, Astbury S, Cheng AC, et al. Multicentrerandomised double-blind placebo controlled trial of combination vancomycin and cefazolin surgical antibiotic prophylaxis: the Australian surgical antibiotic prophylaxis (ASAP) trial. BMJ Open. 2019;9(11):e033718. doi:10.1136/bmjopen-2019-033718
Oriol I, Sabé N, Simonetti AF, et al. Changingtrends in the aetiology, treatment and outcomes of bloodstreaminfectionoccurring in the first year after solidorgantransplantation: a single-centre prospectivecohort study. Transpl Int. 2017;30(9):903-913. doi:10.1111/tri.12984
Johnson K, Boucher HW. Editorial commentary: imminent challenges: carbapenem-resistant enterobacteriaceae in transplant recipients and patients with hematologic malignancy. Clin Infect Dis. 2014 ;58(9):1284-1286. doi:10.1093/cid/ciu056
Chan S, Ng S, Chan HP, et al. Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant recipients. Cochrane Database Syst Rev. 2020;8(8):CD013209. doi:10.1002/14651858.CD013209.pub2. PMID: 32799356; PMCID: PMC7437398.
Chen HY, Jean SS, Lee YL, et al. Carbapenem-resistant enterobacterales in long-term care facilities: a global and narrative review. Front Cell Infect Microbiol. 2021;11:601968. doi:10.3389/fcimb.2021.601968
Surveillance of antimicrobial resistance in Europe. ECDC. 2017. Accessed August 11, 2022. https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2017
van Duin D, Arias CA, Komarow L, et al. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect Dis. 2020;20(6):731-741. doi:10.1016/S1473-3099(19)30755-8
Chen YP, Liang CC, Chang R, et al. Detection and colonization of multidrug resistant organisms in a regional teaching hospital of Taiwan. Int J Environ Res Public Health. 2019;16(7):1104. doi:10.3390/ijerph16071104
Avery RK. Recipient screening prior to solid-organ transplantation. Clin Infect Dis. 2002;35(12):1513-1519. doi:10.1086/344777
McFarlane AC, Kabbani D, Bakal JA, Smith SW. Clinical impact of vancomycin-resistantenterococcicolonization in nonliversolidorgantransplantation and itsimplications for infection control strategies: a single-center, 10-year retrospective study. Transp lInfect Dis. 2021;23(6):e13747. doi:10.1111/tid.13747
Logre E, Bert F, Khoy-Ear L, et al. Risk factors and impact of perioperative prophylaxis on the risk of extended-spectrum β-lactamase-producing Enterobacteriaceae-related infection among carriers following liver transplantation. Transplantation. 2021;105(2):338-345. doi:10.1097/TP.0000000000003231
Taimur S, Pouch SM, Zubizarreta N, et al. Impact of pre-transplant carbapenem-resistant Enterobacterales colonization and/or infection on solid organ transplant outcomes. Clin Transplant. 2021;35(4):e14239. doi:10.1111/ctr.14239
Cies JJ, Palladino C, Mahmood H, Moore WS, Chopra A. Targeted multidrug resistant organism antimicrobial prophylaxis and postoperative infections in pediatric cardiothoracic surgical patients. Pediatr Infect Dis J. 2020;39(6):514-518. doi:10.1097/INF.0000000000002620
Sarwar S, Koff A, Malinis M, Azar MM. Daptomycin perioperative prophylaxis for the prevention of vancomycin-resistant Enterococcus infection in colonized liver transplant recipients. Transpl Infect Dis. 2020;22(3):e13280. doi:10.1111/tid.13280
Mularoni A, Bertani A, Vizzini G, et al. Outcome of transplantation using organs from donorsinfected or colonized with carbapenem-resistant Gram-negative bacteria. Am J Transplant. 2015;15(10):2674-2682. doi:10.1111/ajt.13317
Giani T, Conte V, Mandalà S, et al. Cross-infection of solid organ transplant recipients by a multidrug-resistant Klebsiella pneumoniae isolate producing the OXA-48 carbapenemase, likely derived from a multiorgan donor. J Clin Microbiol. 2014;52(7):2702-2705. doi:10.1128/JCM.00511-14
Ariza-Heredia EJ, Patel R, Blumberg EA, et al. Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae. Transpl Infect Dis. 2012;14(3):229-236. doi:10.1111/j.1399-3062.2012.00742.x
Xiao J, Wu D, Jia Y, Wan Q, Peng J. Impact of donor-derived multi-drug-resistant organism infections on abdominal solid organ transplantation recipients in China. Transplant Proc. 2021;53(6):1853-1857. doi:10.1016/j.transproceed.2021.04.014
Anesi JA, Blumberg EA, Han JH, et al. Impact of donor multidrug-resistant organisms on solid organ transplant recipient outcomes. Transpl Infect Dis. 2022;24(1):e13783. doi:10.1111/tid.13783
Wan Q, Liu H, Ye S, Ye Q. Confirmed transmission of bacterial or fungal infection to kidney transplant recipients from donated after cardiac death (DCD) donors in China: a single-center analysis. Med Sci Monit. 2017;23:3770-3779. doi:10.12659/msm.901884
Errico G, Gagliotti C, Monaco M, et al. Colonization and infection due to carbapenemase-producingEnterobacteriaceae in liver and lungtransplantrecipients and donor-derived transmission: a prospectivecohort study conducted in Italy. ClinMicrobiolInfect. 2019;25(2):203-209. doi:10.1016/j.cmi.2018.05.003
Wolfe CR, Ison MG. Donor-derived infections: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13547. doi:10.1111/ctr.13547
Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation. 2000;101(25):2916-2921. doi:10.1161/01.cir.101.25.2916